Retrospective evaluation of human genetic evidence for clinical trial success using Mendelian randomization and machine learning

Charles N. J. Ravarani[1,†], Marius Arend[1,†], Hannes A. Baukmann[1], Justin L. Cope[1], Margaretha R. J. Lamparter[1], James K. Sullivan[1], Roman Fudim[1], Andreas Bender[2], Anders Mälarstig[3], Marco F. Schmidt[1,*]

[1]biotx.ai GmbH, Am Mühlenberg 11, 14476 Potsdam, Germany

[2]Center for Biotechnology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates

[3]Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77 Stockholm, Sweden

[†]These authors contributed equally to this work.

*e-Mail: ms@biotx.ai

Abstract

Human genetics has become a cornerstone of drug target discovery, yet the value of Mendelian randomization (MR) for predicting clinical success remains uncertain. Here, we systematically evaluated MR across 11,482 target–indication pairs with documented Phase II clinical outcomes to assess its utility for drug development. We find that MR statistical significance alone does not enrich for Phase II success, in contrast to genome-wide association study (GWAS) support, which confers an increase in success probability. However, this apparent limitation reflects the heterogeneous nature of clinical failure and the fact that MR encodes information beyond P values. When MR-derived features, including instrument strength and explained variance, are integrated into machine learning models, predictive performance improves substantially. An MR-informed XGBoost classifier identifies target–indication pairs with a 55% overall approval rate, corresponding to a 6.4-fold enrichment over unstratified programs and a 2.8-fold improvement over GWAS-supported targets in Phase II. Notably, this enrichment is achieved without reliance on statistically significant MR results. Our findings demonstrate that MR is most informative when treated as a graded, context-dependent source of causal evidence rather than a binary hypothesis test, and that its integration with machine learning enables scalable, genetics-informed prioritization of drug targets across the clinical pipeline.

Introduction

The overall probability that a drug candidate progresses successfully through all three clinical trial phases is only around 10%.[1] Phase II has the lowest success rate of all three clinical trial phases, with only 30%—this is where clinical efficacy is tested for the first time.[2,3] This highlights a central challenge in drug development: the difficulty of accurately predicting clinical efficacy of a drug candidate.

Demonstrating clinical efficacy is achieved through a prospective, randomized, placebo-controlled trial, which represents the gold standard for establishing causality. Outside of biomedicine, due to time and cost constraints, causality can only be investigated prospectively to a limited extent. As a result, a variety of statistical methods have been developed to estimate causal relationships retrospectively from observational data—collectively known as causal inference.[4]

In parallel, human genetics has had a profound impact on pharmaceutical development: Naturally occurring genetic mutations in humans—often referred to as "experiments of nature"—can provide insights into the likely efficacy and potential on-target toxicity of drugs that modulate the corresponding protein targets. These genetic variations help establish relationships between perturbation of a target and clinical outcomes.[5] Analyses have demonstrated that drug targets with genetic support—i.e., genes associated with the disease through genome-wide association studies (GWAS)—are significantly more likely to succeed in Phase II trials.[6–8] This insight is already being implemented in practice by the pharmaceutical industry; in 2021, two-thirds of FDA-approved drugs had some form of human genetic evidence.[9] Mutations that cause monogenic diseases have been shown to be strong predictors of clinical efficacy.[8] This is because the causal link between the gene (product) and the disease is typically well understood and firmly established. Applying causal

inference to GWAS data in order to validate drug targets and predict efficacy in

polygenic diseases thus represents a logical and increasingly adopted strategy in

pharmaceutical research.

Mendelian randomization (MR) is a key causal inference method that uses genetic

variants as instrumental variables (IVs) to estimate the causal effect of an exposure

(e.g., a biomarker or gene target) on a disease outcome.[10,11] Because genetic

variants are randomly allocated at conception according to Mendel's laws, they are

typically independent of the confounding factors that complicate traditional

observational studies—assuming the variant affects the outcome only through the

exposure of interest. MR is therefore highly valuable for drug development, as it can

help determine not just whether a target is relevant, but whether it should be

inhibited or activated.[12]

Although the concept of MR dates back to the 1980s,[13] its practical application has

expanded rapidly in recent years due to the availability of extensive biobank datasets

and advances in computational infrastructure.

To enable a large-scale, retrospective application of MR to drug development, we

leveraged a dataset curated by Minikel *et al.*[8], which includes clinical trial outcomes

for 25,713 drug target–indication pairs (TIPs). We enriched this dataset with GWAS

summary statistics (Fig. 1a): 10,207 blood expression and blood protein quantitative

loci (e/pQTL) drug-target biomarker studies, resolving 2,204 distinct gene products

(Fig. 1b), as exposures and 1,653 disease studies, corresponding to 413 unique

indications (Fig. 1c), as outcomes. This allowed us to map at least one exposure or

outcome dataset for 18,386 TIPs in the retrospective trial data (Supplementary Table

1 & 2) enabling MR runs for these TIPs. In addition, we created a random negative

control sample of 14,889 random combinations of targets and indications featured in

the retrospective data with available genetic datasets but no retrospective data on

drug trial success.

We used our standardized clumping pipeline to investigate MR predictions resulting

from instrument sets selected with different clumping parameters (see Methods for

details). This dataset formed the basis of our retrospective analysis of the predictive

power of MR drug trial outcome prediction. We set out to first check for statistical

enrichment of Phase II successful TIPs among significant MR results. Subsequently,

we combined these MR results, with additional features from GWAS metadata and

drug or disease types and trained different machine learning classifiers to predict

Phase II successful TIPs (Fig. 1a). We used a 9-fold crossvalidation scheme to

validate our models on unseen Out-Of-Bag (OOB) samples.

Altogether, we present the first large-scale retrospective evaluation of human genetic

evidence on clinical trial success using Mendelian randomization and machine

learning.

Results

Mendelian randomisation analyses of 11,482 target-indication pairs (TIPs)

We identified 18,368 target-indication pairs (TIPs) within the dataset of 25,713 TIPs

of successful and failed drug developments curated by Minikel *et al.*[8], that had both

exposure and outcome datasets available. Mendelian randomization analyses were

successfully performed for 17,190 TIPs, and 11,482 TIPs had documented outcomes

from Phase II clinical trials (Supplementary Table 3), classified as either successful

or failed. The results for these 11,482 TIPs are summarized in confusion matrices

shown in Fig. 2.

TIPs were classified according to the presence or absence of GWAS support, based

on the annotation provided by Minikel *et al.*[8] Among TIPs without GWAS support, the

ratio of successful to failed Phase II trials was 1,802:9,170, whereas for TIPs with

GWAS support, the ratio was 153:357 (Fig. 2a). This corresponds to a 2.25-fold

higher likelihood of Phase II success for TIPs supported by GWAS evidence. The

association was highly significant, as determined by a chi-squared test ($P < 0.0001$).

Initial screening with MR using a default significance threshold of $P < 0.05$, resulted

in a ratio of 1,788:8,788 successful versus failed trials for TIPs without MR support,

compared to 167:739 TIPs with MR support (Fig. 2b). No significant association

between MR support and Phase II trial outcome was observed, as indicated by a

non-significant chi-squared test.

When applying a Bonferroni-corrected significance threshold ($P < 2.2 \times 10^{\square\square}$), we

did not observe major shifts in the subsequent ratios resulting in 1,947:9,505 for TIPs

without MR support and 8:23 for TIPs with MR support (Fig. 2c). Consequently, no

significant difference in Phase II success rates was detected based on more

stringent MR support to type I errors, as confirmed by a non-significant chi-squared

test.

For the amount of compounds that failed primarily due to toxicity or strategic reasons

rather than lack of target validity in the retrospective data,[14] we employed the

DisGeNET[15] gene-disease-association database as a source of biological evidence

independent of MR. When mapping DisGeNET scores to the TIPs in the

retrospective trial data we could confirm that TIPs bearing a DisGeNET score higher

than 0.3 (DisGeNET support) are more successful in clinical trials than the average

(Extended Data Fig. 1). Still, the majority of TIPs with DisGeNET support fail prior to

Phase II. To generate accuracy estimates that are unaffected by failed compounds

with target validity, we constructed a negative set including random combinations of

targets and indications from retrospective trial data stratified for the target types and

disease areas in Phase II successful TIPs (Supplementary Table 3). Any random

combinations with reported Phase II success as well as an associated DisGeNET

score higher than 0.3 were filtered out. Using this negative control, the ratio of

successful to failed trials was 1,947:9,513 for TIPs without MR support and 8:14 for

TIPs with MR support. This resulted in a precision of 0.36 and yielded a statistically

significant chi-squared test result, indicating an enrichment beyond random

expectation.

Machine learning using Mendelian randomization–derived features

From the 11,482 TIPs, 10,334 TIPs were used to train two machine learning

classifiers, random forest and XGBoost, to distinguish successful from failed Phase II

trials, as well as from a random negative control, using 9-fold cross-validation.

Features included MR-derived variables (MR method, P value, absolute effect size,

confidence level, number of instruments, instrument R^2, and F-statistic), as well as

cohort size (exposure and outcome), target class, and disease category

(Supplementary Table 3). Precision–recall curves were computed across all out-of-

bag (OOB) predictions.

Consistent with expectations, both classifiers showed improved performance when

trained against the random negative control compared with failed trials (Fig. 3), with

XGBoost consistently outperforming random forest (Extended Data Fig. 2a,b). For

the random negative control, XGBoost achieved an AUPR of 0.65 using all features,

compared with 0.49 when excluding MR features (Fig. 3a). Similarly, for failed trials,

inclusion of MR features improved performance (AUPR 0.46 vs 0.35; Fig. 3b).

Across both XGBoost models, the most influential features were the instrument F-
statistic and instrument R^2 (Fig. 3c,d). Correlation analysis revealed minimal feature

redundancy, with correlation observed only between the number of instruments and

the number of individuals in the exposure dataset (Extended Data Fig. 3).

To enable direct comparison, random forest and XGBoost models were additionally

trained using GWAS support, as reported by Minikel *et al.*[8], as a feature. Inclusion of

GWAS support did not improve model performance. Overall, MR-derived features

consistently provided greater predictive value than GWAS support alone across all

machine learning models evaluated (Extended Data Fig. 2a).

Effect of instrument selection and clumping parameters on classifier
performance

To assess the impact of instrument selection and clumping parameters on classifier

performance, Mendelian randomization analyses were repeated for all 11,482 TIPs

using four additional parameter combinations in addition to the default settings

(genome-wide clumping window: 10,000 kb, r² = 0.001, $P < 5 \times 10^{\square\square}$;

Supplementary Table 5). When modulating clumping parameters, we observed

differences in classifier performance barely above the standard error from cross

validation, independent of the classifier design, negative set or used feature set

(Extended Data Fig. 4a,b). Conversely the XGBoost classifier trained on features

including MR results depicted the best performance in all four investigated clumping

parameter combinations, with the default parameters providing the best basis to

segregate successful from Phase II failed TIPs.

When we investigated the association between significant MR results and Phase II

successful TIPs (as presented in Fig. 2 for default parameters) a stronger impact of

clumping parameters was observed (Extended Data Fig. 5a,b). However, chi-

squared tests remain insignificant for all four parameter sets, when segregating

failed from Phase II successful retrospective TIPs (Extended Data Fig. 5a).

A different picture emerges when investigating the segregation of random negative

TIPs. In this scenario the highly significant chi-squared test result for the default

parameter sets is even further improved and the strength of association increases by

31% when reducing the clumping window from the defaull 10,000 kb to 100 (Fig 2d &

Extended Data Fig. 5b).

Retrospective clinical enrichment across genetically and model-prioritized

target-indication pairs

Of the 10,334 TIPs used for 9-fold cross-validated machine learning analyses, 9,776

TIPs had available final clinical approval data. As shown in Fig. 4, across all TIPs

entering preclinical development, 54% progressed to Phase I (5,315 TIPs), 70% of

these advanced to Phase II (3,729 TIPs), 32% progressed to Phase III (1,202 TIPs),

and 70% of Phase III programs ultimately achieved regulatory approval (840 TIPs).

Overall, 840 of 9,776 TIPs (8.6%) were successful.

Among the 417 TIPs with GWAS support (as reported by Minikel *et al.*[8]), progression

rates were higher at each stage: 56% reached Phase I (234 TIPs), 81% reached

Phase II (189 TIPs), 54% reached Phase III (103 TIPs), and 83% achieved approval

(86 TIPs). This corresponds to an overall success rate of 20%, representing a 2.4-

fold increase compared with TIPs without GWAS support.

The out-of-bag (OOB) predictions of theXGBoost classifier identified 149 TIPs as

successful drug targets. Of these, 85% reached Phase I (127 TIPs), 92% reached

Phase II (117 TIPs), 79% reached Phase III (93 TIPs), and 88% achieved approval

(82 TIPs), yielding an overall success rate of 55%. Relative to unstratified TIPs,

model-supported TIPs were 6.4-fold more likely to succeed and 2.8-fold more likely

to succeed than TIPs supported by GWAS alone. Phase II success rates increased

from 32% without prior support to 54% with GWAS support and 79% when prioritized

by the machine learning model. Notably, among the 9,776 TIPS, 417 were supported

by GWAS and 149 were identified by the ML model using MR-informed features,

with only 12 overlapping hits; accordingly, the Jaccard index between the GWAS-

supported and MR+ML-selected sets was 0.02, indicating that the two approaches

capture largely complementary signals.

Characteristics of top TIPs predicted by the MR-informed classifier

Based on predictions from the best-performing classifier incorporating MR-derived

features, 93 Phase II–successful TIPs were identified. The top ten of these TIPs with

the highest predicted probability of success are reported in Table 1. Comparison

between two most important features contributing to classifier performance and the *P*

value from MR analysis showed that none of the predicted successful TIPs were

associated with a significant MR result.

The majority of the 93 correctly predicted TIPs comprised kinase targets associated

with oncologic indications. In contrast, the five TIPs with the most significant MR

results were associated with diverse indications and a variety of targets, each

engaged by specific drugs (Supplementary Table 6).

To further characterize these differences, the association between MR significance

and Phase II success was evaluated as a function of the number of indications per

target. Significant MR results were enriched among successful Phase II targets that

had been trialed in a limited number of specific indications (chi-squared test, *P* <

0.001; Extended Data Fig. 6a). This association was not observed for targets that

had been trialed in more than five indications. Additionally, targets evaluated across

multiple indications were less frequently trialed in metabolic and endocrine diseases

and more frequently trialed in dermatologic and oncologic indications (Extended

Data Fig. 6b).

Discussion

In this study, we performed MR analyses across 11,482 TIPs with documented

Phase II clinical outcomes to systematically evaluate the utility of genetic causal

inference for predicting drug development success. While prior work has

demonstrated that GWAS support is associated with increased probability of clinical

success, the added value of MR, particularly at scale and across heterogeneous

indications, has remained unclear. Our results provide a nuanced answer: MR

significance alone does not directly enrich for Phase II success (Fig. 2b,c), yet MR-

derived features substantially improve predictive performance when integrated into

machine learning models (Fig. 3a,b), yielding strong retrospective clinical enrichment

(Fig. 4).

Across the full set of 11,482 Phase II annotated TIPs, we observed no statistically

significant association between MR significance and Phase II trial success,

regardless of whether nominal (Fig. 2b) or Bonferroni-corrected thresholds (Fig. 2c)

were applied. This finding contrasts with the clear enrichment observed for GWAS-

supported TIPs, which showed a 2.25-fold increase in Phase II success rates (Fig.

2a). At face value, this result may appear to challenge the utility of MR for target

prioritization.

However, several considerations likely explain this apparent discrepancy. First,

beyond the MR P value, other parameters such as instrument strength (F-statistic),

explained variance (R^2), and consistency across different MR methods carry

important information about the reliability and interpretability of genetic evidence.[16] In

this context, direct comparison of MR significance with binary GWAS support using

confusion matrices is likely to be misleading. Second, Phase II failure is a

heterogeneous endpoint that conflates lack of target validity with non-biological

causes such as toxicity, formulation challenges, competitive landscape changes, or

strategic portfolio decisions. Consistent with this interpretation, independent

biological evidence from DisGeNET demonstrated that many TIPs that fail prior to or

during Phase II nevertheless show strong gene–disease associations, suggesting

that failure in clinical development does not imply absence of biological relevance

(Extended Data Fig. 1). As a consequence, retrospective analyses that treat all failed

programs as true negatives are inherently biased against causal inference methods

such as MR, which are designed to assess biological validity rather than downstream

development feasibility.

Indeed, when we constructed a random negative control explicitly designed to

minimize biologically valid target–disease pairs, MR support showed significant

enrichment beyond random expectation (Fig. 2d). This result supports the conclusion

that MR signals are diluted in conventional retrospective trial datasets by a

substantial fraction of biologically valid but clinically unsuccessful programs.

While MR P values alone were not predictive of Phase II success, integrating MR-

derived features into machine learning models substantially improved performance.

Both random forest and XGBoost classifiers consistently benefited from inclusion of

MR features, with XGBoost achieving the strongest results (Extended Data Fig.

2a,b). Importantly, MR-derived features outperformed GWAS support in performance

(Fig. 3b), and adding GWAS support to the models did not further improve predictive

accuracy (Extended Data Figs. 2a, 4a).

The most influential features across all models were the instrument F-statistic and

instrument R^2 (Fig. 3c,d), both of which quantify the strength and explanatory power

of the genetic instruments. These features capture information orthogonal to binary

GWAS annotations, reflecting not merely the presence of genetic association but the

robustness, consistency, and statistical leverage of the underlying genetic

architecture. The minimal redundancy observed among numerical features

(Extended Data Fig. 4) further indicates that MR-derived variables encode

complementary information rather than recapitulating cohort size or target class

effects.

These findings suggest that MR should not be viewed as a hypothesis-testing filter at

the level of individual TIPs, but rather as a feature generator that encodes graded

evidence of genetic causality, which can be exploited by downstream statistical

learning approaches.

Systematic evaluation of instrument selection thresholds and linkage disequilibrium

clumping parameters demonstrated that classifier performance was generally robust,

with default MR settings performing near-optimally (Extended Data Fig. 4a,b).

Modest gains were observed for more relaxed *P* value thresholds and reduced gene

windows, suggesting that tighter localization of genetic effects may marginally

improve signal-to-noise ratios in some contexts. However, these improvements were

incremental, indicating that the core conclusions are not sensitive to specific MR

parameter choices.

From a practical standpoint, this robustness is encouraging, as it supports the

scalability of the approach and reduces the need for extensive parameter tuning

when applying MR-informed models in real-world target prioritization settings.

When applied retrospectively across the full drug development pipeline, the MR-

informed XGBoost classifier identified a subset of TIPs with dramatically improved

clinical outcomes. Model-prioritized TIPs achieved an overall success rate of 55%,

representing a 6.4-fold enrichment over unstratified programs and a 2.8-fold

enrichment over GWAS-supported TIPs. Phase II success rates increased from 32%

in the unstratified set to 54% with GWAS support and to 79% among model-

prioritized TIPs (Fig. 4). Across the 9,776 TIPS, GWAS supported 417 and MR+ML

identified 149, with only 12 overlapping hits (Jaccard index = 0.02), indicating largely

complementary signals. Notably, 11/12 overlapping targets succeeded in Phase II,

9/12 were approved, and only 1/12 stopped in Phase I, suggesting that MR+ML adds

orthogonal evidence to GWAS and that concordant hits may be especially strong

predictors of clinical success.

These results indicate that integrating MR-derived features with machine learning

can identify target–indication pairs that are not only biologically plausible but also

disproportionately successful across multiple stages of development, including

regulatory approval. Importantly, this enrichment was achieved without relying on

statistically significant MR results, underscoring that weak or sub-threshold MR

signals can still be highly informative when interpreted in aggregate.

Analysis of the characteristics of top model-predicted TIPs revealed an apparent

paradox: the majority of correctly predicted Phase II successful TIPs did not exhibit

significant MR P values (Table 1). Instead, significant MR results were enriched

among targets tested in a limited number of indications (Extended Data Fig. 6),

whereas targets trialed broadly across multiple indications, particularly kinases in

oncology, rarely showed strong MR significance despite high clinical success rates.

This observation highlights a fundamental limitation of MR in multi-indication

settings. When a target is deployed across diverse disease contexts, the genetic

signal for any single indication may be diluted or obscured by pleiotropy, context-

specific mechanisms, or limited power in individual GWAS datasets. In contrast, MR

appears more effective at detecting causal effects in narrow, well-defined indication

spaces, where genetic perturbations more closely mirror pharmacologic intervention.

Taken together, these findings suggest that MR significance should be interpreted as

context-dependent evidence rather than a universal indicator of target quality, and

that its greatest value lies in contributing structured, quantitative features to

integrative prioritization frameworks.

This study has several limitations that should be considered when interpreting the

results. First, all Mendelian randomization analyses were based on eQTL and pQTL

exposure datasets derived from blood. While blood-based molecular QTLs are

among the most comprehensive and well-powered resources currently available,

gene expression and protein abundance in blood represent a heterogeneous mixture

of cell types and may not fully capture tissue- or cell-type–specific regulatory effects

relevant to many disease mechanisms. Incorporation of exposure datasets from

additional tissues, such as those generated by GTEx[17] or emerging single-cell QTL

resources such as OneK1K[18], may further refine causal estimates and improve

model performance, particularly for indications driven by non-hematopoietic tissues.

Second, we relied on the target–indication annotation curated by Minikel *et al.*[8],

which represents an industry-standard, publicly available dataset and ensures that

our analyses are fully reproducible. However, this resource has several important

limitations. For a subset of drugs, the true molecular target remains a matter of
ongoing scientific debate, leading to potential ambiguity in target assignment. In
particular, many small-molecule drugs exhibit polypharmacology and engage
multiple targets, a complexity that is not captured by the single target-indication pairs
represented in the Minikel dataset. As a result, genetic effects attributed to a single
annotated target may, in practice, reflect a composite of on- and off-target
mechanisms. In addition to that, this resource does not encode the directionality of
pharmacologic modulation, i.e., whether a given drug acts as an inhibitor or activator
of its target. As a result, we were unable to leverage one of the key strengths of
Mendelian randomization—directional interpretation of causal effects—to align
genetic estimates with the mechanism of action of individual compounds. Availability
of drug mechanism annotations would likely enhance future models by enabling
concordance-based filtering between genetic effect direction and therapeutic
modulation, and thereby further improve target prioritization performance. Finally, as
with all Mendelian randomization studies, our analyses rely on core assumptions,
including the absence of unmeasured horizontal pleiotropy and the validity of linear,
lifelong genetic effects as proxies for time-limited pharmacologic intervention, which
may not hold uniformly across all targets and indications.

In summary, our results demonstrate that while Mendelian randomization does not,
by itself, enrich for Phase II success in retrospective clinical datasets, MR-derived
features substantially enhance predictive models of drug development success when
combined with machine learning. This approach outperforms GWAS support alone
and yields strong enrichment across the full clinical pipeline. These findings argue for
a shift in how MR is used in drug discovery: from a binary causal test to a component

of multidimensional, data-driven target prioritization strategies and provide a scalable

framework for integrating human genetics into translational decision-making.

Materials & Methods

Retrospective clinical dataset and genetic annotation

The main source of evidence for drug target success in a certain indication was the

information available in the published Supplementary Table 1 of Minikel *et al.*[8], which

indicates the maximum reached phase in completed and ongoing clinical trials for a

given target–indication pair (TIP). Detailed information on the original compilation is

available per the original publication.[8] Briefly, Minikel *et al.*[8] queried the Citeline

Pharmaprojects database (December 22nd 2022) to retrieve monotherapy

programmes added since 2000 annotated with a highest phase reached, a human

gene target and a clinical indication defined using the Medical Subject Headings

(MeSH) ontology. Combination therapies, programmes without a human target, and

entries lacking indication assignments were removed, and each remaining TIP was

annotated with the most advanced phase recorded for any drug targeting that gene

in that indication. Effectively splitting drugs with multiple targets, into independent

target–indication combinations. Minikel *et al.*[8] generated standardized trial

information for a total of 25,713 TIPs.

Minikel *et al.*[8] also assembled a harmonized database of human genetic

associations, aggregating gene–trait links from disparate sources including Online

Mendelian Inheritance in Man (OMIM), curated genome-wide association studies

(GWAS) and other cohorts, with both indications and genetically associated traits

mapped to MeSH terms to standardize phenotypes across datasets. A binary

annotation of genetic support was assigned to a TIP if (i) there existed at least one

human genetic association linking the target gene to a trait and (ii) the MeSH term

for that trait attained a semantic similarity score ≥ 0.8 to the MeSH term for the

corresponding clinical indication, as computed via an ontology-based similarity

metric. This annotation is referred to as GWAS support when used as a benchmark

in this manuscript.

Disgenet and negative control dataset

As an additional negative evaluation set we generated random combinations of

targets and indications included in the retrospective trial data[8] irrespective of trial

outcome. We stratified by target type and disease area distribution in the set of

Phase II successful TIPs when drawing random targets and indications, respectively.

To filter TIPs with biological evidence from the set of random negative TIPs we

sourced information from the DisGeNET database[15] (March 10th 2022). The

DisGeNET database provides a score for ranking of TIPs that summarises evidence

from expert curated databases, animal models, clinical trials, human phenotype

ontology, and scientific literature mining. We excluded any random combination of

target and disease if it was included in the DisGeNET database with a score >0.3 or

existed in the set of Phase II successful TIPs.

Genetic exposure and outcome datasets

To enable MR runs on a scale comparable to the presented evaluation data we

compiled a large data set harmonized and standardized GWAS data. We included

summary statistics from 10,207 blood e/pQTL datasets resolving 2,204 distinct gene

products (Fig. 1b, Supplementary Table 7) and 1,653 disease studies, corresponding

to 413 unique indications (Fig. 1c, Supplementary Table 8).

Datasets were pre-processed with version 1.11.8 of the tool MungeSumstats[19] using

default parameters that include checking to ensure variants are on the respective

human reference genome (GRCh37 or GRCh38, depending on the dataset),

removing duplicate single nucleotide polymorphisms (SNPs), and removing multi-

allelic SNPs (according to the SNP database db144).

To facilitate the integration with the TIP evaluation annotation, harmonized and

standardized datasets were assigned a Disease Ontology ID for the measured

disease indication[20] or an ENSEMBL Gene ID representing the measured gene

product (in the case of eQTL and pQTL datasets). These standardized ids were then

used to map datasets to retrospective trial information. To this end, mesh ids in

Supplementary Table 1 of Minikel *et al.*[8] were mapped to Disease Ontology ids using

the Disease Ontology and DisGeNET cross-reference database. Gene Names in

Supplementary Table 1 of Minikel *et al.*[8] were mapped to ENSEMBL gene ids using

the uniprot API. The mapping allowed to assign each retrospective trial TIP any

available e/pQTL datasets for use as exposure and any available disease GWAS

datasets for use as outcome in a mendelian randomization experiment, to test for

causal effect.

Mendelian randomization framework

Different clumping parameters were used depending on the scope of the exposure

study (cis *vs.* trans QTLs). No other data set-dependent distinctions in clumping

parameters were made in order to ensure comparability of the selected instruments

between different exposure QTL studies. If not mentioned otherwise the values

indicated as "default" in Supplementary Table 5 were used in the subsequently

described steps. First, pre-processed summary statistics files were read and

thresholds were applied to the exposure SNPs to ensure they were valid

instruments. Independent SNPs were identified by performing linkage disequilibrium

(LD) clumping to discard SNPs in LD with another variant with a smaller P value

association based on the European reference panel from the 1,000 Genomes

Project[21] using the ld_clump() function of the R package ieugwasr[22](version 1.0.1),

which provides a wrapper around PLINK[23]. The correlation LD clumping parameter r^2

and haplotype block size are indicated in the respective results. SNPs remaining

after clumping and P value thresholding were overlapped with the SNPs reported in

the outcome dataset and effect directions were harmonized using the

TwoSampleMR package (version 0.6.9)[24], dropping any palindromic SNPs. The

remaining overlapping SNPs represent the list of Instrumental Variables employed in

subsequent MR analysis.

Based on the selected m Instrumental Variables, R^2 and F-statistic as measures of

their jointly explained variance have been calculated[25]:

$$(1) \quad R^2 = \sum_{i=1}^{m} \frac{\beta_i^2}{\beta_i^2 + SE(\beta_i)^2 \cdot n_{ind}},$$

$$(2) \quad F = \frac{R^2}{1-R^2} \cdot \frac{n_{ind}-m-1}{m},$$

where β gives the reported effect size and n_{ind} the number of individuals in the

exposure data set. $SE(\beta)$ refers to the standard error of β.

If at least three SNPs remained as instrumental variables, the MR-Rücker

framework[24] was applied to determine which random effects modelling framework of

the inverse-variance weighted (IVW)[26] or the MR-Egger[27] method was best

supported by the data and results from the respective MR method were used. If only

two SNPs remained as instrumental variables, the IVW method was applied, or if

only one, the Wald ratio method[28]. The used method is indicated in Supplementary

Table 3 and Supplementary Table 9 gives the distribution of used methods in the

results evaluated in this study.All methods were implemented in the TwoSampleMR

package[24] (version 0.6.9).

Enrichment and validation analyses

In order to evaluate performance and train machine learning classifiers we assigned

the TIPs into sets with clear binary annotation indicating whether a TIP was Phase II

successful (positive) or not (negative).

The first set is purely based on TIPs with retrospective information on clinical trials.

TIPs have been assigned as positives and negatives according to the following rules:

1. TIPs with completed trial status and a maximum reached phase below phase II

were assigned as negatives and TIPs with a higher phase as positives.

2. TIPs with ongoing trial status in the database provided by Minikel *et al.*[8] (queried

December 22nd 2022) and a maximum reached phase below phase II were treated

as unclassifiable and excluded from the set and TIPs with a higher phase as

positives.

The second set combines phase II successful TIPs from retrospective data with a

sample of random TIPs as negatives. TIPs in this set have been assigned based on

the following rules:

1. TIPs with a maximum reached phase above phase II were assigned as positives.

All other TIPs with retrospective trial information were excluded from the set.

2. All randomly sampled TIPs (filtered for DisGeNET score < 0.3) were treated as

negatives.

We subsampled a number of random TIPs with MR results that ensured this second

evaluation data set has the same cardinality and balance as the first set.

We calculated 2x2 confusion matrices between the evaluation annotation of a TIP

(Phase II successful vs negative) and different binary predictors: (i) GWAS support

as reported by Minikel *et al.*[8] or (ii) MR significance at different significance levels α.

We used established values of 0.05 and 0.0001 as well as, 2.112 x 10^{-6}, a Bonferroni

corrected value taking into account the number of all MR experiments (The

respectively used α is indicated in the result figure or the text section). After

obtaining the respective confusion matrix, the chi-squared test[29] was used to test for

a significant association between prediction and ground truth. Association strength

has been measured using Cramer's V.

Machine learning models and feature engineering

To improve on the performance of the raw *P* value as sole predictor of TIP success

we trained machine learning classifiers employing different combinations of features

from (i) MR experiments, (ii) the metadata of used GWAS studies, (iii) genetic

support according to Minikel *et al.*[8] as well as (iiii) target and disease type

(Supplementary Table 4).

As a first step in the creation of training data we split off 10% of the TIPs in the two

evaluation data sets as leave-out validation data. The remaining 90% of data were

termed training data and used for model training. For hyperparameter tuning and

performance analysis the training data was used in a 9-fold cross validation

approach.

All machine learning models were trained and evaluated using the R tidymodels

framework (version 1.3.0) together with the ranger package (version 0.18.0) for the

generation of random forest classifiers[30] and the XGBoost package (version 3.1.3.1)

for the generation of XGBoost classifiers[31]. Hyperparameters were tuned for using

the mr results obtained with default clumping parameter and models harbouring

metadata and mr features. Hyperparameter tuning was performed employing a 9-fold

cross validation approach on 90% of the total data. For the random forest classifiers

a grid of values for the hyperparameters number of trees, number of features

selected per split and minimum node size were scanned (Supplementary Table 10).

For XGBoost classifiers we uniformly sampled 60 hyperparameter combinations from

the space spanned by the hyperparameters number of trees, number of features

selected per split, minimum node size, learning rate, and minimum loss reduction

(Supplementary Table 11). For both classifiers the hyperparameter set maximising

the mean AUPRC from crossvalidation was used to train all other machine learning

models of the same classifier type.

Model evaluation and sensitivity analyses

To evaluate the model performance we calculated AUPRC values for each fold and

report the mean and standard error as over all cross-validation folds. IPR curves

were plotted over the aggregated OOB predictions for each data point in the training

data set.

Feature importances presented for XGBoost classifiers in this paper have been

calculated as fractional gain,[31] the relative reduction of variance summed over all

splits in which the respective variable was used and weighted over all trees,

normalized to the total reduction of variance achieved by the classifier. The fractional

gain was calculated using the implementation of the XGBoost R package (version

3.1.3.1). In case of categorical features that have been transformed using one-hot

encoding, the feature importances of all resulting features have been summed and

are   reported   as   per   the   original   categorical   feature.

These feature importance calculations have been run for each fold of the cross-

validation and mean and standard error over all folds are reported.

Retrospective clinical progression analysis

To calculate funnel width representing the number of TIPs that were evaluated up to

a certain Phase of clinical development we only considered completed trial TIPs in

the 90% training data, excluding any annotation from ongoing trials at the time of the

citeline database query (December 22nd 2022). Starting from the total set of trialed

TIPs in preclinical evaluation we calculate the relative and absolute numbers of

these TIPs that were evaluated at each successive stage. We did this for three sets:

(a) all TIPs with retrospective information in the training data. (b) The subset of these

TIPs that were deemed "genetically supported" in the study from Minikel *et al.*[8] and

(c) another subset of all TIPs with retrospective information that were predicted as

successful by the best performing random forest classifier. We choose a probability

threshold for success prediction that delivers the same recall as achieved by set (b).

If $N(i)$ indicates the number of drugs evaluated in stage i of the evaluation pipeline

we calculated the probability of a random drug in the selection to advance to the next

stage, $P(i, i + 1)$, as:

575   (3) $P(i, i + 1) = \frac{N(i+1)}{N(i)}$

Acknowledgements

This work was partially supported by Germany`s Federal Agency for Breakthrough

Innovation (SPRIN-D) through a validation project. The analyses were supported by

NVIDIA Corporation through the *NVIDIA Inception program* and by Google LLC

through the *Google for Startups Cloud Program*. We thank Radi Hilaneh for

preparing Figures 1–4, and Jack Scannell and Hubert Truebel for proofreading the

manuscript.

Competing interests

586 C.N.J.R., M.A., H.A.B., J.L.C., M.R.J.L., J.K.S, R.F. and M.F.S. are employees of

587 biotx.ai GmbH. A.M. was an employee of Pfizer Research and Development at the

588 time this work started and is now an employee of Novo Nordisk A/S.

References

1. Roland, A., Fox, W. & Baker, A. Efficiency, effectiveness and productivity in

pharmaceutical R&D. *Nat. Rev. Drug Discov.* **23**, 656–657 (2024).

2. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J.

Clinical development success rates for investigational drugs. *Nat. Biotechnol.* **32**,

40–51 (2014).

3. Mullard, A. Parsing clinical success rates. *Nat. Rev. Drug Discov.* **15**, 447

(2016).

4. Pearl, J. Causal inference in statistics: An overview. *Stat. Surv.* **3**, 96–146

(2009).

5. Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets

through human genetics. *Nat. Rev. Drug Discov.* **12**, 581–594 (2013).

6. Nelson, M. R. *et al.* The support of human genetic evidence for approved drug

indications. *Nat. Genet.* **47**, 856–860 (2015).

7. King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support

twice as likely to be approved? Revised estimates of the impact of genetic

support for drug mechanisms on the probability of drug approval. *PLoS Genet.*

15, e1008489 (2019).

8. Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of

genetic evidence on clinical success. *Nature* **629**, 624–629 (2024).

9. Ochoa, D. *et al.* Human genetics evidence supports two-thirds of the 2021 FDA-

approved drugs. *Nat. Rev. Drug Discov.* **21**, 551 (2022).

10. Angrist, J. D., Imbens, G. W. & Rubin, D. B. Identification of causal effects using

instrumental variables. *J. Am. Stat. Assoc.* **91**, 444–455 (1996).

11. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization

analysis with multiple genetic variants using summarized data: Mendelian

randomization using summarized data. *Genet Epidemiol* **37**, 658–665 (2013).

12. Burgess, S. *et al.* Using genetic association data to guide drug discovery and

development: Review of methods and applications. *Am. J. Hum. Genet.* **110**,

195–214 (2023).

13. Katan, M. B. Apolipoprotein E isoforms, serum cholesterol, and cancer. *Lancet*

1, 507–508 (1986).

14. Bowling, H., Cocucci, A., Koo, D. C. E. & Harrison, R. K. Analysis of phase II and

phase III clinical trial terminations from 2013 to 2023. *Nat. Rev. Drug Discov.*

(2025) doi:10.1038/d41573-025-00208-6.

15. Piñero, J. *et al.* DISGENET: Accelerating data-driven discovery in disease

genomics and therapeutic development. *bioRxiv* 2026.01.05.697749 (2026)

doi:10.64898/2026.01.05.697749.

16. Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian

randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* **362**,

k601 (2018).

17. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects

across human tissues. *Science* **369**, 1318–1330 (2020).

18. Yazar, S. *et al.* Single cell eQTL mapping identified cell type specific control of

autoimmune disease. *Science* **376**, (2022).

19. Murphy, A. E., Schilder, B. M. & Skene, N. G. MungeSumstats: a Bioconductor

package for the standardization and quality control of many GWAS summary

statistics. *Bioinformatics* **37**, 4593–4596 (2021).

20. Schriml, L. M. *et al.* Human Disease Ontology 2018 update: classification,

content and workflow expansion. *Nucleic Acids Res.* **47**, D955–D962 (2019).

21. Fairley, S., Lowy-Gallego, E., Perry, E. & Flicek, P. The International Genome

Sample Resource (IGSR) collection of open human genomic variation

resources. *Nucleic Acids Res.* **48**, D941–D947 (2020).

22. Interface to the OpenGWAS Database API. https://mrcieu.github.io/ieugwasr/.

23. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-

based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).

24. Bowden, J. *et al.* A framework for the investigation of pleiotropy in two-sample

summary data Mendelian randomization. *Stat. Med.* **36**, 1783–1802 (2017).

25. Pierce, B. L., Ahsan, H. & Vanderweele, T. J. Power and instrument strength

requirements for Mendelian randomization studies using multiple genetic

variants. *Int. J. Epidemiol.* **40**, 740–752 (2011).

26. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization

analysis with multiple genetic variants using summarized data. *Genet.*

Epidemiol. **37**, 658–665 (2013).

27. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with

invalid instruments: effect estimation and bias detection through Egger

regression. *Int. J. Epidemiol.* **44**, 512–525 (2015).

28. Wald, A. The fitting of straight lines if both variables are subject to error. *Ann.*

Math. Stat. **11**, 284–300 (1940).

29. Agresti, A. *An Introduction to Categorical Data Analysis_*. (John Wiley & Sons,

New York, 2007).

30. Wright, M. N. & Ziegler, A. Ranger: A fast implementation of random forests for

high dimensional data in C++ and R. *J. Stat. Softw.* **77**, (2017).

31. Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. *arXiv*

[cs.LG] (2016) doi:10.48550/ARXIV.1603.02754.

Figures

Fig. 1

Fig. 1. Study design and dataset overview. (a) Overview of used data, employed models and validation approaches. **(b)** Upset plot indicating the overlap in coverage for drug-targets resolved in the e/pQTL studies used as exposures (any overlaps including more than 20 targets are shown). **(c)** Upset plot indicating the overlap in coverage for indication resolved in disease GWAS studies used as outcomes (any overlaps including more than 5 indications are shown).

Fig. 2

Fig. 2. Phase II successful TIPs are enriched in significant MR results and

GWAS support. (a,b) Confusion matrix and *P* value from chi-squared test results for

enrichment of Phase II successful TIPs with **(a)** GWAS support according to Minkel

et al.[8] or MR results with below standard significance threshold **(b)** or bonferroni

corrected significance threshold. **(c)**. Values are calculated using all TIPs for which

retrospective information confirmed failure Prior to Phase III as negatives (Failed

trials). **(d)** Confusion matrix and *P* value from chi-squared test results for enrichment

of Phase II successful TIPs with significant MR results using a random sample of TIP

as negatives. The random sample was filtered for TIPs without retrospective

information on Phase II success and without DisGeNET score > 0.3 and stratified for

disease area and target type (Random Neg. Control).

 Fig. 3

Fig. 3. Classification of Phase II successful drugs is improved by Mendelian Randomization features. (a,b) Precision recall (PR) curves for the classification of Phase II successful TIPs versus **(a)** randomly generated TIPs for which no retrospective information on Phase II success is available or **(b)** clinically trialed TIPs that failed prior to Phase III. PR curve was calculated over all OOB predictions in 9-

fold cross-validation. Curves indicate performance values for a XGBoost classifier

using all features (orange), the same model trained without MR features (grey), and

the theoretical performance of a classifier that assigns positives randomly based on

the number of positives in the validation set (red). The green dot indicates the

performance of the binary variable indicating GWAS support from Minikel *et al.*[8] as a

classifier on the same set. **(c,d)** Mean feature importance (fractional gain) from 9-fold

cross-validation of XGBoost models trained on the data used in (a) or (b),

respectively. Bars give the mean and whiskers the standard error. The color code

indicates the source of the feature.

Fig. 4

Fig. 4. Positives predicted by best MR supported machine learning outperform

GWAS supported TIPs. Success chances and funnel chart of different drug sets in

the failed trail data set. Overall: all TIPs with retrospective information available

(blue, n = 9,776), TIPs with GWAS associated variants according to Minikel *et al.*[8]

(green, n = 417). TIPs predicted as positives in OOB sets by best performing random

forest classifier (orange, n = 149). Among 9,776 TIPS, GWAS supported 417 and

MR+ML identified 149, with only 12 overlapping TIPs (Jaccard index = 0.02),

indicating largely complementary signals.

Tables

Table 1

Table 1. Phase II successful TIPs with highest predicted success probability

from best performing classifier. Minikel GWAS Support[8] is indicated and the

associated values of the features, Instrument F-score, Instrument R^2 and MR *P* value

are reported. Rows are ordered by decreasing success probability.

Rank	Target gene	Indication	Minikel GWAS Support	Instrument R^2	Instrument F-score	MR *P* value	Success Probability (Classifier)
1	*FLT4*	Gastrointestinal Stromal Tumors	No	0.084	227	0.7176	0.953
2	*TYMS*	Arthritis, Juvenile	No	0.053	37	0.6447	0.924
3	*KIT*	Gastrointestinal Stromal Tumors	Yes	0.067	86	0.8569	0.921
4	*IFNAR2*	COVID-19	Yes	0.058	491	0.1924	0.919
5	*KIT*	Neuroendocrine Tumors	No	0.067	86	0.3470	0.915
6	*FGFR2*	Carcinoma, Non-Small-Cell Lung	No	0.015	59	0.8459	0.914
7	*F10*	Hemophilia A	Yes	0.012	76	0.5354	0.912
8	*ERBB4*	Carcinoma, Non-Small-Cell Lung	No	0.049	108	0.7945	0.911
9	*IL1B*	COVID-19	No	0.018	992	0.3896	0.909
10	*TEK*	Carcinoma, Non-Small-Cell Lung	No	0.112	263	0.9894	0.900

 Extended Data

 Extended Data Fig. 1

Extended Data Fig. 1. Retrospective trials with DisGeNET support showed a higher proportion of successful TIPs. The barplot visualized the distribution of maximum reached phases for all completed trials in the retrospective data (turquoise) and the subset with DisGeNET support[15]. DisGeNET support was assigned if a TIP is associated with a DisGeNET score higher than 0.3.

Extended Data Fig. 2

Extended Data Fig. 2. Random Forest and XGBoost classifier depict similar

dependency on MR features (a) Precision recall (PR) curves for the classification

of Phase II successful drug-target indication pairs (TIPs) versus TIPs that failed prior

to Phase III. PR curve was calculated over all Out-Of-Bag prediction in 9-fold cross-

validation. Curves indicate performance values for a random forest or XGBoost using

different combinations of metadata (Meta), MR result (MR) and Minikel et al.[8] GWAS

support features (Minikel). The baseline indicates the theoretical performance of a

classifier that assigns positives randomly based on the number of positives in the

validation set (baseline). The green dot indicates the performance of the binary

variable indicating GWAS support from Minikel et al. as a classifier on the same set.

(b) Same as in (a) but the negative set consists of random combinations of targets

and indications for which no retrospective information on Phase II Success is

available, stratified for disease area and target type in the set of Phase II successful

TIPs.

Extended Data Fig. 3

Extended Data Fig. 3. Numerical MR and GWAS derived features show overall

low correlation. Correlation matrix of the numerical features derived from MR

results and GWAS metadata calculated over the entire training data obtained using

the **(a)** random control or **(b)** failed trials as negatives.

Instrument Parameters	default	high pvalue	high R^2	100kb range
p (trans / cis)	5e-8/1e-4	5e-4/5e-2	-	-
R^2 (trans / cis)	0.001/0.1	-	0.2/0.4	-
Range [kb]	10000	-	-	100

Extended Data Fig. 2. Overview of classifier performance for different models,

features and instrument selection schemes. (a,b) AUPRC curves for the

classification of Phase II successful TIPs versus **(a)** TIPs of failed trials **(b)** random

TIPs or **(c)**. AUPR was calculated separately for each OOB set in 9-fold cross-

validation of the 90% training data. Bar plot indicates mean and standard error of

AUPRC of a random forest or XGBoost classifier using the indicated features (see

also **Supplementary Table 4**) The x-axis indicates the different instrument selection

scheme used for MR analysis, with the table indicating exact values used for

clumping and instrument selection. All models were trained on the intersection of

TIPs with available MR results in all instrument selection schemes.

 Extended Data Fig. 5

Extended Data Fig. 5: Clumping parameter selection has strong influence on MR significance predictiveness. (b,d) Predictive power of the MR *P* value given by Cramer's V association strength between significant MR results ($\square$ = 0.0001) and Phase II successful TIPs vs **(a)** TIPs of failed trials **(b)** random TIPs in the evaluation data. Asterisks indicate associated Chi-squared test significance level. All statistics were calculated on the intersection of TIPs with available MR results in all instrument selection. Significancy asterisk code: * *P* < 0.05; ** *P* <0.01; *** *P* <0.001.

777 **Extended Data Fig. 6**

778
Extended Data Fig. 6. Target trial specificity differs between disease areas and

affects MR predictivity. (a) Predictive power of the MR *P* value as given by

Cramer's V for targets grouped by the amount of indications they have been clinically

trialed for (irrespective of trial outcome). Cramer's V and *P* value are calculated

based on the association between Phase II successful TIPs and significant MR

results (α = 0.0001). Negatives: Failed trials. Chi-squared test results indicated by

asterisks. **(b)** Change in the number of TIPs associated with each disease area

compared to the most specific target TIPs (1-5 tested indications). Bins have been

chosen to be as equally sized as possible without overlaps. Bin sizes: n (1-5) =

2,337; n (6-10) = 2,318; n (11-17) = 2,281; n (18-27) = 2,311; n (28-66) = 2,235.

Significancy asterisk code: * *P* < 0.05; ** *P* <0.01; *** *P* <0.001.